Исследование щитовидной железы в ядерной медицине

al. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. // Cancer - 1993 — Vol. 71. — P. 3767-3773.

O'Driscoll C.M., Baker F., Casey M.J., Duffy G.J. Localization of recurrent medullary thyroid carcinoma with technetium-99m-methoxyisobutylnitrile scintigraphy: a case report. // J Nucl Med — 1991 — Vol. 32. — P. 2281-2283.

Briele B., Hotze A.L., Kropp J., et al. Comparison of 99mTc-MIBI and Tl-201-chloride in the follow-up of patients with differentiated thyroid carcinoma. // J Nucl Med — 1992 — Vol. 33. — P. 844.

Mojiminiyi O.A., Udelsman R., Soper N.D., et al. Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid. // Clin Nucl Med. — 1991 — Vol. 16 — P. 259-262.

Frilling A., Tecklenborg K., Gorges R., et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. // Ann Surg — 2001 — Vol. 234. — P. 804-811.

Diehl M., Risse J.H., Brandt-Mainz K., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. // Eur J Nucl Med — 2001 — Vol. 28. — P. 1671-1676.

Helal B.O., Merlet P., Toubert M.E., et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. // J Nucl Med — 2001 — Vol. 42. — P. 1464 - 1469.

Shiga T., Tsukamoto E., Nakada K., et al. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. // J Nucl Med — 2001 — Vol. 42. — P. 414-419.

Petrich T., Borner A.R., Otto D., et al. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. // Eur J Nucl Med — 2002 — Vol. 29. — P. 641-647.

Van Tol K.M., Jager P.L., Piers D.A., et al. Better yield of 18Fluorodeoxyglucose-Positron Emission Tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. // Thyroid — 2002 — Vol. 12. — P. 381-387.

Tisell L.E., Ahlman H., Wangberg B., et al. Somatostatin receptor scintigraphy in medullary thyroid carcinoma. // Br J Surg — 1997 — Vol. 84. — P. 543-547.

Adams S., Baum R.P., Hertel A., et al. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. // Eur J Nucl Med — 1998 — Vol. 25. — P. 1277 — 1283.

Postema P., De Herder W., Reubi J.C., et al. Somatostatin receptor scintigraphy in nonmedullary thyroid cancer. // Digestion — 1996 — Vol. 1 (Suppl.). — P. 36-37.

Gulec S.A., Serafini A.N., Sridhar K.S., et al. Somatostatin receptor expression in Hurthle cell cancer of the thyroid. // J Nucl Med — 1998 — Vol. 39. — P. 243-245.

Haslinghuis L.M., Krenning E.P., de Herder W.W., et al. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. // J Endocrinol Invest — 2001 — Vol. 24. — P. 415-422.

Waldherr C., Pless M., Maecke H.R., et al. The clinical value of [90YDOTA]- D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. // Ann Oncol — 2001 — Vol. 12. — P. 941- 945.

Paganelli G., Zoboli S., Cremonesi M., et al. Receptormediated radiotherapy with 90Y-DOTA-D-Phe1- Tyr3-octreotide. // Eur J Nucl Med — 2001 — Vol. 28. — P. 426-434.

Valkema R., Jamar F., Bakker W.H., et al. Safety and efficacy of [Y-90-DOTA,Tyr(3)]- octreotide (Y-90-SMT487;OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study. // Eur J Nucl Med — 2001 — Vol. 28. — P. 1025.

Kwekkeboom D.J., Kam B.L., Bakker W.H., et al. Treatment with 177Lu-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors. // J Nucl Med — 2002 — Vol. 43. — 34P.

Kwekkeboom D.J., Bakker W.H., Kooij P.P., et al. [177Lu- DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. // Eur J Nucl Med — 2001 — Vol. 28. — P. 1319-1325.

Ain K.B., Taylor K.D., Tofiq S., Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. // J Clin Endocrinol Metab — 1997 — Vol. 82. — P. 1857-1862.

Reubi J.C., Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. // Int J Cancer - 1996 — Vol. 67 — P. 644-647.

Kwekkeboom D.J., Bakker W.H., Kooij P., et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. // Eur J Nucl Med — 2000 — Vol. 27. — P. 1312-1317.

Behr TM, Bйhй MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin- B receptor-expressing malignancies. // Sem Nucl Med - 2002 — Vol. 32. — P. 97-109.




8-09-2015, 18:58

Страницы: 1 2
Разделы сайта